Overview
An immune-system booster.
Approved in 35+ countries (as Zadaxin) for chronic hepatitis.
Not approved in the US.
What It Does
Master immune regulator – approved in 35+ countries for hepatitis, cancer, and immune deficiency.
Promotes T-cell differentiation.
Activates dendritic cells, NK cells, and cytotoxic T-lymphocytes.
Modulates Th1/Th2 balance.
Reconstitution
| Vial Size | BAC Water / Solvent | Concentration |
|---|---|---|
| 5 mg | + 1 mL | 5 mg/mL |
| 10 mg | + 2 mL | 5 mg/mL |
Reconstitution Calculator
Enter the vial amount and diluent volume to calculate concentration. If you already have a target amount, you can also convert it to liquid volume and syringe markings. This tool does not recommend a target amount.
Enter a target amount you already have and select the syringe capacity.
Mathematical reference only. The calculator does not determine an appropriate target amount. Syringe capacity only changes the maximum volume that fits.
Protocol
| Phase | Frequency | Amount | Notes |
|---|---|---|---|
| Standard | 2×/week | 1.6 mg | FDA Zadaxin label: 1.6 mg twice weekly, 3–4 days apart. Source previously read 3x/week. |
| Immune boost | Daily × 4 weeks | 1.6 mg | Intensive course. |
| Off | 4 weeks | – | Essential break between cycles. Skipping leads to tolerance and diminishing returns. |
6–12 weeks on, 4 weeks off.
2×/week SubQ, 3–4 days apart (Zadaxin label)
Unisex immune modulator, same protocol for men and women / protocol, no cycle effect; used in both sexes clinically. Avoid in pregnancy.
Handling & Stacking
- Freeze-dried: -4°F.
- Reconstituted: 36–46°F.
- Best used within ~3–4 weeks, kept cold (structure-based estimate, no published data); that is close to the 28- day sterility limit, so use whichever comes first.
- Immune improvement over 4–12 weeks.
- CD4/CD8 ratio and NK counts are measurable endpoints.
- Very well tolerated – one of the safest immune peptides available.
- Supply math 5mg → 4 vials | 10mg → 2 vials (6-wk @ 1.6 mg × 2/wk)
Safety & Patient Education
- Immunosuppressants (cyclosporine, tacrolimus, sirolimus, mycophenolate, methotrexate): pharmacologically opposed; T1 augments T-cell function while these suppress it.
- Combining is generally inappropriate outside a specialist-supervised protocol Corticosteroids (chronic systemic): blunt the T1 immune response; coordinate dosing or pause steroids during a T1 course where clinically possible Live vaccines: theoretical augmented response, coordinate timing with the prescriber TNF-alpha inhibitors and other biologics (adalimumab, etanercept, infliximab, rituximab): mechanistically opposed for autoimmune indications; not advisable to combine without specialist oversight Antiviral therapy for hepatitis B/C: T1 is studied as adjunct (Zadaxin label uses it that way), synergistic, not antagonistic
- Used clinically as an adjunct to antiviral therapy for chronic hepatitis B and C in countries where Zadaxin is approved.
- Cyclic dosing (typically 1.6 mg SubQ 2× weekly for 4–12 weeks) is the canonical pattern; continuous dosing isn’t supported by the literature.
- Quality and authenticity vary widely in the US compounding market, verify supplier and request COA.
- Stop and contact a clinician for any new joint pain, rash, fevers, or symptoms suggesting an autoimmune flare.
